New Target Identified to Sensitize Glioblastoma to Treatment

Scientists have identified a weakness in glioblastoma, the most lethal brain tumor. In preclinical studies, blocking the protein SET stopped tumor formation, while inhibiting related proteins increased the cancer cells’ sensitivity to radiation. The approach works by reactivating PP2A, an enzyme that glioblastoma cells normally suppress. The findings suggest that targeting SET and its network could undermine the tumor’s defense mechanisms and improve treatment outcomes. The next step is human trials to assess safety and effectiveness.